These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 32008109)

  • 1. Antibody-Drug Conjugates in Urothelial Carcinomas.
    Sarfaty M; Rosenberg JE
    Curr Oncol Rep; 2020 Feb; 22(2):13. PubMed ID: 32008109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates for urothelial carcinoma.
    Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
    Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of antibody-drug conjugates in urothelial carcinoma.
    Lattanzi M; Rosenberg JE
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
    Halford Z; Anderson MK; Clark MD
    Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.
    D'Angelo A; Chapman R; Sirico M; Sobhani N; Catalano M; Mini E; Roviello G
    Cancer Chemother Pharmacol; 2022 Sep; 90(3):191-205. PubMed ID: 35953604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives.
    Alameddine R; Mallea P; Shahab F; Zakharia Y
    Curr Treat Options Oncol; 2023 Sep; 24(9):1167-1182. PubMed ID: 37403009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [ANTIBODY-DRUG CONJUGATES - A NOVEL APPROACH FOR THE TREATMENT OF METASTATIC UROTHELIAL CARCINOMA].
    Sternschuss M; Sarfaty M
    Harefuah; 2022 Jan; 161(1):49-54. PubMed ID: 35077061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
    McGregor BA; Sonpavde G
    Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside.
    Ungaro A; Tucci M; Audisio A; Di Prima L; Pisano C; Turco F; Delcuratolo MD; Di Maio M; Scagliotti GV; Buttigliero C
    Cells; 2022 Feb; 11(5):. PubMed ID: 35269424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
    Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
    Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Drug Conjugates in Bladder Cancer.
    Vlachostergios PJ; Jakubowski CD; Niaz MJ; Lee A; Thomas C; Hackett AL; Patel P; Rashid N; Tagawa ST
    Bladder Cancer; 2018 Jul; 4(3):247-259. PubMed ID: 30112436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer.
    Alhalabi O; Altameemi L; Campbell MT; Meric-Bernstam F
    Cancer J; 2022 Nov-Dec 01; 28(6):417-422. PubMed ID: 36383903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
    Yu J; Wu S; Li R; Jiang Y; Zheng J; Li Z; Li M; Xin K; Guan X; Li S; Chen X
    J Hematol Oncol; 2023 Jul; 16(1):85. PubMed ID: 37507780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
    Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
    Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma.
    Abel M; Burkenroad A; Sun A; Lu E; Stefanoudakis D; Drakaki A
    Clin Genitourin Cancer; 2021 Jun; 19(3):183-193. PubMed ID: 33558159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape.
    Ghose A; Lapitan P; Apte V; Ghosh A; Kandala A; Basu S; Parkes J; Shinde SD; Boussios S; Sharma A; Das P; Vasdev N; Rebuzzi SE; Ürün Y; Kanesvaran R; Maniam A; Banna GL
    Curr Oncol Rep; 2024 Jun; 26(6):633-646. PubMed ID: 38652426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development.
    Kwon WA; Lee SY; Jeong TY; Kim HH; Lee MK
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
    Singh AM; Guevara-Patino JA; Wang X; Li R; Sonpavde G; Jain RK
    BioDrugs; 2023 Jul; 37(4):505-520. PubMed ID: 37256534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.